Project description:Nanostring nCounter Human miRNA assay (v1) of esophageal mucosal biopsies from children with eosinophilic esophagitis and controls Individual esophageal mucosal biopsies from children with eosinoniphilic esophagitis and controls were analysed for detection of microRNA

2014-09-01 | E-GEOD-55794 | biostudies-arrayexpress

Gene expression-based, treatment response analyses using Nanostring nCounter

Project description:Background: Despite availability of effective treatment regimens for drug-susceptible TB, some patients still experience poor treatment outcomes. Currently tools for monitoring treatment outcomes are dependent on detection of mycobacteria in sputum, which are slow, expensive and poor at predicting relapse and failure. This study aims to identify new blood-derived markers for predicting treatment response and outcomes. Methods: Whole blood was collected in PAXgene tubes from patients with microbiologically confirmed TB at diagnosis, week 2, and at month 2, 4 and 6. Treatment response and outcomes were determined by culture and gene expression was compared between slow and fast responders; and between patients with good (cured) and poor treatment outcomes (failure and recurrent TB) using targeted RNA gene expression. Gene signatures were developed using random forest classification models. Results: Significant changes in gene expression were detected over the course of the TB treatment. Notably, major gene expression differences were observed at diagnosis between subsequently cured patients and patients who experienced poor treatment outcomes while minimal changes were detected between slow and fast responders among cured patients at diagnosis. A 7-gene end of treatment signature distinguished patients with good outcomes from those with poor treatment outcomes with AUCs of 0.91, 0.98, and 1.0 at baseline, month 2 and month 6 respectively. Additionally, a 6-gene month 2 signature discriminates slow from fast responders with AUCs of 0.49, 0.57, and 0.93 at diagnosis, week 2 and month 2 respectively. Conclusion: The study identified genes signatures associated with TB treatment response and outcomes suggesting potential utility for treatment monitoring

2025-08-13 | GSE295312 | GEO

Gene expression analysis of chicken p. major muscle using the NanoString nCounter technology

Project description:Tissue samples were harvested with the Keyes biopsy punch (8 mm; manufactured by HNM) from the caudal edge of the right superficial pectoral muscle perpendicular to myofibers and to the keel bone. Total RNA was isolated from p. major samples using mirVana™ miRNA Isolation Kit. Quality checks were performed by measuring the concentration and “RNA Integrity Number” of individual RNA samples using NanoDrop 1000 and Agilent Bioanalyzer 2100. The RNA samples were normalized and sent to NanoString Inc. (Seattle, WA, USA) for the quantification of gene expression levels using NanoString nCounter® technology. For this, 192 target genes, along with 12 housekeeping genes were selected based on multiple RNA-seq experiments conducted in our laboratories.

2021-01-11 | GSE162634 | GEO

Nanostring nCounter human miRNA assay (v1) of eosinophilic esophagitis

Project description:Nanostring nCounter Human miRNA assay (v1) of esophageal mucosal biopsies from children with eosinophilic esophagitis and controls

2014-09-01 | GSE55794 | GEO

NanoString nCounter NF1-mutant melanoma gene expression

Project description:NanoString nCounter NF1-mutant melanoma gene expression

| PRJNA827162 | ENA

Transcriptomic analsyis of Epithelial and Mesenchymal carcinoma cells using the nCounter PanCancer Immune Profiling panel (Nanostring Technologies) [mouse]

Project description:We undertook to determine whether carcinoma cells residing in the epithelial or quasi-mesenchymal phenotypic states differ in their expression of immunomodulatory markers. To do so, we used the nCounter PanCancer Immune Profiling Panel (Nanostring Technologies)to perform transcriptomic analyses of the E and qM mammary carcinoma cells; these cells were either cultured in vitro or prepared by FACS sorting of GFP-labelled carcinoma cells from their corresponding tumors

2021-09-15 | GSE161746 | GEO

Nanostring nCounter Bovine Arrival BRD 60 Panel v1.0

Project description:Nanostring nCounter Bovine Arrival BRD 60 Panel v1.0

| PRJNA744165 | ENA